Tuberculosis Trial, Recruiting NCT06590428 Sponsor: Albert Einstein College of Medicine Condition: Tuberculosis
Back to Tuberculosis

Tuberculosis Trial, Recruiting

NCT06590428
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must have been diagnosed with a type of tuberculosis (TB) that does not respond to the antibiotic rifampicin, confirmed by a lab test
  • You must have started a TB treatment plan that includes the medication linezolid no more than 14 days before joining the trial
  • Your HIV status must be known — both people who are HIV-positive and HIV-negative are welcome to join
  • If your HIV status is unknown, you must agree to take an HIV test at the time of enrollment to be eligible

Who may not be able to join:

  • You may not be able to join if you have a serious medical condition where doctors expect you may not survive the next 7 days
  • You may not be able to join if you are pregnant at the time of screening
  • You may not be able to join if your starting dose of linezolid is less than 600mg per day
  • You may not be able to join if you have a severe form of TB that has spread outside the lungs to areas such as the brain lining, the heart lining, or the bones
  • You may not be able to join if it is unlikely that you would be able to attend follow-up appointments at Nkqubela Hospital based on where you live

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: James CM Brust, MD, Albert Einstein College of Medicine

Phone: 718-920-6482

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Albert Einstein College of Medicine
Registry
ClinicalTrials.gov
Start date
7 April 2026
Est. completion
1 June 2029

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

Discontinuation of Linezolid or non-TDM guided dose reduction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov